Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.63 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22899588 | 0.98 | SIGMAR1 (0.65) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| SCHEMBL143708 | 0.98 | SIGMAR1 (0.65) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Bromide SCHEMBL1331742 | 0.95 | SIGMAR1 (0.63) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Ammonia Solution, Strong SCHEMBL15917374 | 0.95 | SIGMAR1 (0.63) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Methyl Alcohol SCHEMBL29261100 | 0.93 | SIGMAR1 (0.61) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL3332713 | 0.92 | SIGMAR1 (0.55) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Toluene SCHEMBL27514860 | 0.92 | SMN1; SMN2 (0.61) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Alcohol SCHEMBL9136417 | 0.89 | SIGMAR1 (0.57) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL27850743 | 0.88 | SIGMAR1 (0.52) | SIGMAR1CYP3A4MAPTKDM4EPOLB | |
| Putrescine SCHEMBL8006412 | 0.86 | SIGMAR1 (0.53) | SIGMAR1CYP3A4MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107376615-A | A kind of highly efficiency compositional desulfurization and decarburization solvent and its application | 中国石油集团工程设计有限责任公司 | 2017-11-24 | — | — | CN | claimed |
| EP-2729169-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | Nanobio Corporation (US) | 2014-05-14 | — | — | EP | claimed |
| WO-2013006797-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION (US) | 2013-01-10 | — | — | WO | claimed |
| CN-118771989-A | Method for catalyzing hydrosilation reduction of amide into amine by using tridentate nitrogen ligand manganese complex | 浙江工业大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-116887806-A | Improved long-wearing sun-proof cosmetic | 巴斯夫欧洲公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-104629792-B | The removal methods of nitride in a kind of heavy oil | ZHEJIANG OCEAN UNIVERSITY (CN) | 2016-04-27 | — | — | CN | disclosed |
| CN-104629792-A | Method for removing nitride from heavy oil | UNIV ZHEJIANG OCEAN | 2015-05-20 | — | — | CN | disclosed |
| US-8962662-B2 | Antimicrobial compositions and methods of use thereof | BYOCOAT ENTERPRISES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8586115-B2 | Antimicrobial solutions and process related thereto | BYOCOAT ENTERPRISES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130137732-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | BYOCOAT ENTERPRISES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013074526-A2 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | BYOCOAT ENTERPRISES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2007030104-A1 | ANTIMICROBIAL SOLUTIONS AND PROCESS RELATED THERETO | BYOCOAT ENTERPRISES, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060110506-A1 | Antimicrobial solutions and process related thereto | BYOCOAT ENTERPRISES, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050271781-A1 | Antimicrobial solutions and process related thereto | BYOCOAT ENTERPRISES, INC. | 2005-12-08 | — | — | US | disclosed |
| EP-0065804-B1 | PROCESS FOR THE PREPARATION OF N-BENZYL-N-ISOPROPYL PIVALAMIDE | HÜLS AKTIENGESELLSCHAFT (DE) | 1984-12-12 | — | — | EP | disclosed |
| EP-0065804-A1 | Process for the preparation of N-benzyl-N-isopropyl pivalamide | HÜLS AKTIENGESELLSCHAFT (DE) | 1982-12-01 | — | — | EP | disclosed |
| US-4331815-A | Process for manufacturing N-benzyl-N-isopropyl amides | GULF OIL CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| US-4119729-A | TREATMENT OF HYPERTENSION | MEAD JOHNSON & COMPANY (US) | 1978-10-10 | — | — | US | disclosed |
| US-4067904-A | ANTIARRHYTHMIA, HYPOTENSIVE | MEAD JOHNSON & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137732-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF | KARS1, AAAS, AARS1 | SIGMAR1 793/4885HRH1 3366/4885CYP3A4 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.